https://www.selleckchem.com/pr....oducts/pf-06952229.h
3% (4/75) vs 23.4% (33/144)] and no visible residual disease (R cytoreduction rate in the NACT+IDS group were significantly higher [(41.3% (31/75) vs 61.7% (87/144); all P0.05). Conclusions Normal CA125 before IDS and time received chemotherapy no longer than 7 days after IDS are two related factors of prognosis benefit in advance EOC patients treated with NACT+IDS. Therefore, timely adjustment of the dose and regimen of NACT to reduce CA125 level to normal range in about three cycles before IDS, and strengthen IDS perioperative m
Like
Comment
Share
